Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Mass-testing reduced Liverpool COVID-19 cases by a fifth, study finds

Published 07/06/2021, 07:13 PM
Updated 07/06/2021, 08:30 PM
© Reuters. FILE PHOTO: People queue at the coronavirus disease (COVID-19) testing centre in Liverpool, Britain November 6, 2020. REUTERS/Carl Recine

LONDON (Reuters) - A mass rapid-testing scheme reduced COVID-19 cases in the English city of Liverpool by more than a fifth, researchers said on Wednesday, arguing it was an effective public health intervention despite concerns over accuracy of the devices.

The community testing pilot scheme launched in November, and offered everyone in the city tests whether or not they had symptoms, in an attempt to find a new way to use testing to limit the spread of the coronavirus.

The study, led by the University of Liverpool with government backing, concluded that community testing led to an 18% increase in case detection and a 21% reduction in cases compared with other areas up to mid-December.

The spread of the Alpha variant first identified in Kent made comparisons between areas more difficult after that point, the researchers said.

"The Liverpool pilot showed that community testing can work, and it works well if it is nationally flexible and locally grounded," Iain Buchan, the University of Liverpool professor leading the trial, told reporters.

Some scientists have questioned the use of rapid lateral flow tests, saying they might do more harm than good, and the U.S. regulator has warned that the performance of the Innova test in use in Britain has not been adequately established.

Despite concerns about the lower accuracy of lateral flow tests compared to PCR tests, the Liverpool researchers said that the devices identified most cases with a high viral load.

The rapid turnaround times had a benefit too, as lateral flow tests give a result in 30 minutes, rather than needing to be processed in a laboratory.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"If it's positive, (people) get immediate reinforcement that they need to take action... we can see it drove down cases," said Calum Semple, Professor of Outbreak Medicine, University of Liverpool.

As part of the study, 283,338 Liverpool residents took a test using a lateral flow device between Nov 6 2020 and April 30 2021.

Latest comments

What happened to batch pool testing?
Crap papper. Vaccines ruduced it nt a fifth
More intentionally false and misleading reports/headlines. There was no proper control group within that community or design study to reach this conclusion, and the article also reports that the conclusion was reach based on data only between November 2020 and mid-December 2020. Cases/deaths have dropped globally independent of testing, vaccination rates, and lockdowns...with the exception of situations where they have intentionally altered the way cases are reported (such as the US FDA limiting the number of PCR cycles to reduce false positives but only in vaccinated people). They are simply using faulty reported research/statistics to push a narrative while failing to point out flaws and opposing data that is also being heavily published but not reported on.
Meant CDC for altering ways cases are counted within the US, not FDA. FDA has not even approved the vaccines.
FDA did, however, require they start putting a warning regarding the vaccines causing heart inflammation.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.